New York, New York--(Newsfile Corp. - October 4, 2018) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Personalized Immunotherapy Could Be the Future for Advanced Breast Cancer Treatment," featuring BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSXV: BCT).
To hear the NetworkNewsAudio version, visit:
To read the full editorial, visit:
It is important to note that immune checkpoint inhibitors such as pembrolizumab (anti-PD-1) and ipilimumab (anti-CTLA-4) have come to the forefront in the fight against cancer with substantial benefits for some patients. The significance of immune checkpoints has been recognized by the Nobel committee by awarding Drs. Honjo (PD-1) and Allison (CTLA-4) with the . This is highly encouraging for BriaCell because the company is using these check point inhibitors in combination with Bria-IMT in its ongoing Phase IIa studies in advanced breast cancer patients.
"We believe that combination studies with immune checkpoint inhibitors should create even more potent anti-cancer immune responses, leading to our strategy of combination studies of Bria-IMT with Keytruda or Yervoy," Williams stated in the press release announcing the results. "In our view, the combination of Bria-IMT with Keytruda or Yervoy has the potential to provide a new therapeutic option and substantial clinical benefit in heavily pre-treated advanced breast cancer patients where there remains a significant unmet need."
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing a targeted and safe approach to the management of cancer. Immunotherapy has come to the forefront in the fight against cancer, harnessing the body's own immune system in recognizing and selectively destroying cancer cells while sparing normal ones. Immunotherapy, in addition to generally being more targeted and less toxic than commonly used types of chemotherapy, is also thought to be a potent approach with the potential to prevent cancer recurrence. For more information, visit the company's website at .
About NetworkNewsAudio
, a Solution, allows you to sit back and listen to market updates, CEO interviews and a Company . These audio clips provide snapshots of position, opportunity and momentum. can assist your company by cutting through the overload of information in today's market, NNA brings its clients unparalleled visibility, recognition and brand awareness. is where news, content and information converge. is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.
For more information, visit:
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: .
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office
